WASHINGTON -- An investigational non-surgical treatment led to a "robust" complete response rate in patients with recurrent, low-grade non-muscle-invasive bladder cancer, the phase III ENVISION study ...
Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. Background: The response to second-line therapies in patients failing BCG is generally very ...
The current standard of care for high-risk superficial bladder cancer is intravesical bacillus Calmette–Guérin (BCG). Electromotive mitomycin has also shown efficacy against high-risk superficial ...
Bladder cancer patterns of pelvic failure: Implications for adjuvant radiation therapy. Background: Combination chemotherapy is the standard of care for neoadjuvant, adjuvant, and metastatic bladder ...
PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today ...
PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
Intravesical therapy is widely used in practice as an adjuvant treatment for early-stage bladder cancer following surgical transurethral resection. This is because it is a localized treatment that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results